Search results for "intestinal morphometry"

showing 4 items of 4 documents

Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.

2013

Endogenous glucagon-like peptide-2 (GLP2) is a key mediator of refeeding-induced and resection-induced intestinal adaptive growth. This study investigated the potential role of GLP2 in mediating the mucosal responses to a chronic high-fat diet (HFD). In this view, the murine small intestine adaptive response to a HFD was analyzed and a possible involvement of endogenous GLP2 was verified using GLP2 (3–33) as GLP2 receptor (GLP2R) antagonist. In comparison with animals fed a standard diet, mice fed a HFD for 14 weeks exhibited an increase in crypt–villus mean height (duodenum, 27.5±3.0%; jejunum, 36.5±2.9%;P<0.01), in the cell number per villus (duodenum, 28.4±2.2%; jejunum, 32.0±2.9%;P&l…

Malemedicine.medical_specialtyDuodenumEndocrinology Diabetes and MetabolismEndogenyBiologyDiet High-Fatdigestive systemJejunumMiceEndocrinologyInternal medicineIntestine SmallmedicineGlucagon-Like Peptide 2Receptors GlucagonAnimalsMolecular Targeted TherapyObesityIntestinal MucosaReceptorCell ProliferationCell growthdigestive oral and skin physiologyGLP2 receptor expression intestinal morphometry obesity intestinal adaptationGlucagon-like peptide-2Adaptation PhysiologicalSmall intestinePeptide FragmentsUp-RegulationMice Inbred C57BLEndocrinologymedicine.anatomical_structureJejunumKi-67 AntigenDuodenumGlucagon-Like Peptide-2 ReceptorAnti-Obesity AgentsGlucagon-Like Peptide-2 ReceptorSignal TransductionThe Journal of endocrinology
researchProduct

Glucagon-like Peptide-2 and mucosal changes induced by high fat diet in mouse small intestine.

2012

GLP2 receptor expression intestinal morphometry obesity intestinal adaptation.Settore BIO/09 - Fisiologia
researchProduct

Role of Endogenous GLP-2 in the Intestinal Adaptation to a Chronic High Fat Diet

2013

GLP-2 receptor expressionintestinal morphometrySettore BIO/09 - Fisiologiaobesity.
researchProduct

A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease

2007

BACKGROUND: Treatment of celiac disease (CD) is based on the avoidance of gluten-containing food. However, it is not known whether trace amounts of gluten are harmful to treated patients. OBJECTIVE: The objective was to establish the safety threshold of prolonged exposure to trace amounts of gluten (ie, contaminating gluten). DESIGN: This was a multicenter, double-blind, placebo-controlled, randomized trial in 49 adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for > or =2 y. The background daily gluten intake was maintained at < 5 mg. After a baseline evaluation (t0), patients were assigned to ingest daily for 90 d a capsule containing 0, 10, or 50 mg glute…

AdultMaleGluten free diet Celiac Diseasemedicine.medical_specialtyGlutensPlacebo-controlled studyMedicine (miscellaneous)gastroenterologyDiseasedigestive systemGastroenterologyCoeliac diseaselaw.inventionRandomized controlled trialDouble-Blind Methodgluten-free dietlawInternal medicineImmunopathologyIntestine SmallMedicineHumansgluten toxicitysmall-intestinal morphometryLymphocyte CountProspective StudiesIntestinal MucosaProspective cohort studyAutoantibodiesceliac disease; gastroenterology; gluten threshold in gluten-free food; gluten threshold in gluten-free food.; gluten toxicity; gluten-free diet; small-intestinal morphometrychemistry.chemical_classificationNutrition and DieteticsDose-Response Relationship Drugbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseGlutendigestive system diseasesgluten threshold in gluten-free foodchemistryToxicityFemalebusinessceliac disease
researchProduct